vs

Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and VIRCO MFG CORPORATION (VIRC). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $47.6M, roughly 1.6× VIRCO MFG CORPORATION). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -42.3%). VIRCO MFG CORPORATION produced more free cash flow last quarter ($24.5M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 5.7%).

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

The Virco Manufacturing Corporation, more commonly known as Virco, is an American furniture manufacturer based in Torrance, California which focuses on providing products for educational markets. The principal products of the company include student desks and activity tables, school and office seating, computer stations, lightweight folding tables, and upholstered chairs.

PBYI vs VIRC — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.6× larger
PBYI
$75.5M
$47.6M
VIRC
Growing faster (revenue YoY)
PBYI
PBYI
+70.1% gap
PBYI
27.7%
-42.3%
VIRC
More free cash flow
VIRC
VIRC
$10.2M more FCF
VIRC
$24.5M
$14.4M
PBYI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
5.7%
VIRC

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
PBYI
PBYI
VIRC
VIRC
Revenue
$75.5M
$47.6M
Net Profit
$-1.3M
Gross Margin
69.3%
38.0%
Operating Margin
22.7%
-3.6%
Net Margin
-2.8%
Revenue YoY
27.7%
-42.3%
Net Profit YoY
-115.8%
EPS (diluted)
$0.26
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBYI
PBYI
VIRC
VIRC
Q4 25
$75.5M
$47.6M
Q3 25
$54.5M
$92.1M
Q2 25
$52.4M
$33.8M
Q1 25
$46.0M
$28.5M
Q4 24
$59.1M
$82.6M
Q3 24
$80.5M
$108.4M
Q2 24
$47.1M
$46.7M
Q1 24
$43.8M
$42.6M
Net Profit
PBYI
PBYI
VIRC
VIRC
Q4 25
$-1.3M
Q3 25
$8.8M
$10.2M
Q2 25
$5.9M
$732.0K
Q1 25
$3.0M
$-5.7M
Q4 24
$8.4M
Q3 24
$20.3M
$16.8M
Q2 24
$-4.5M
$2.1M
Q1 24
$-4.8M
$-2.3M
Gross Margin
PBYI
PBYI
VIRC
VIRC
Q4 25
69.3%
38.0%
Q3 25
77.7%
44.4%
Q2 25
76.5%
47.5%
Q1 25
77.1%
26.2%
Q4 24
76.4%
44.4%
Q3 24
63.9%
46.3%
Q2 24
77.4%
43.5%
Q1 24
75.5%
37.7%
Operating Margin
PBYI
PBYI
VIRC
VIRC
Q4 25
22.7%
-3.6%
Q3 25
17.6%
16.7%
Q2 25
12.7%
-0.3%
Q1 25
8.7%
-28.5%
Q4 24
22.6%
13.5%
Q3 24
27.4%
20.2%
Q2 24
-4.6%
6.4%
Q1 24
-5.3%
-6.5%
Net Margin
PBYI
PBYI
VIRC
VIRC
Q4 25
-2.8%
Q3 25
16.2%
11.1%
Q2 25
11.2%
2.2%
Q1 25
6.5%
-20.1%
Q4 24
10.2%
Q3 24
25.2%
15.5%
Q2 24
-9.6%
4.6%
Q1 24
-11.0%
-5.5%
EPS (diluted)
PBYI
PBYI
VIRC
VIRC
Q4 25
$0.26
$-0.08
Q3 25
$0.17
$0.65
Q2 25
$0.12
$0.05
Q1 25
$0.06
$-0.37
Q4 24
$0.40
$0.52
Q3 24
$0.41
$1.04
Q2 24
$-0.09
$0.13
Q1 24
$-0.10
$-0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBYI
PBYI
VIRC
VIRC
Cash + ST InvestmentsLiquidity on hand
$97.5M
Total DebtLower is stronger
$22.7M
$3.9M
Stockholders' EquityBook value
$130.3M
$113.6M
Total Assets
$216.3M
$181.5M
Debt / EquityLower = less leverage
0.17×
0.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBYI
PBYI
VIRC
VIRC
Q4 25
$97.5M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$101.0M
Q3 24
$96.7M
Q2 24
$96.8M
Q1 24
$107.2M
$5.3M
Total Debt
PBYI
PBYI
VIRC
VIRC
Q4 25
$22.7M
$3.9M
Q3 25
$34.0M
$4.0M
Q2 25
$45.3M
$4.1M
Q1 25
$56.7M
$4.1M
Q4 24
$68.0M
$4.2M
Q3 24
$79.3M
$4.3M
Q2 24
$90.7M
$7.0M
Q1 24
$102.0M
$4.4M
Stockholders' Equity
PBYI
PBYI
VIRC
VIRC
Q4 25
$130.3M
$113.6M
Q3 25
$115.3M
$115.4M
Q2 25
$104.7M
$105.6M
Q1 25
$97.1M
$109.3M
Q4 24
$92.1M
$115.9M
Q3 24
$71.1M
$107.8M
Q2 24
$48.5M
$91.6M
Q1 24
$51.0M
$91.2M
Total Assets
PBYI
PBYI
VIRC
VIRC
Q4 25
$216.3M
$181.5M
Q3 25
$202.9M
$198.6M
Q2 25
$194.9M
$183.8M
Q1 25
$196.2M
$191.9M
Q4 24
$213.3M
$210.1M
Q3 24
$220.7M
$216.3M
Q2 24
$205.0M
$152.5M
Q1 24
$214.1M
$146.4M
Debt / Equity
PBYI
PBYI
VIRC
VIRC
Q4 25
0.17×
0.03×
Q3 25
0.30×
0.03×
Q2 25
0.43×
0.04×
Q1 25
0.58×
0.04×
Q4 24
0.74×
0.04×
Q3 24
1.12×
0.04×
Q2 24
1.87×
0.08×
Q1 24
2.00×
0.05×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBYI
PBYI
VIRC
VIRC
Operating Cash FlowLast quarter
$14.4M
$25.8M
Free Cash FlowOCF − Capex
$14.4M
$24.5M
FCF MarginFCF / Revenue
19.1%
51.5%
Capex IntensityCapex / Revenue
0.0%
2.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M
$-4.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBYI
PBYI
VIRC
VIRC
Q4 25
$14.4M
$25.8M
Q3 25
$9.7M
$3.2M
Q2 25
$14.1M
$-19.0M
Q1 25
$3.6M
$-8.3M
Q4 24
$15.6M
$33.5M
Q3 24
$11.0M
$12.5M
Q2 24
$1.0M
$-4.5M
Q1 24
$11.2M
$4.7M
Free Cash Flow
PBYI
PBYI
VIRC
VIRC
Q4 25
$14.4M
$24.5M
Q3 25
$9.7M
$1.8M
Q2 25
$14.1M
$-21.5M
Q1 25
$3.6M
$-9.2M
Q4 24
$15.6M
$31.0M
Q3 24
$11.0M
$10.7M
Q2 24
$1.0M
$-5.6M
Q1 24
$4.0M
FCF Margin
PBYI
PBYI
VIRC
VIRC
Q4 25
19.1%
51.5%
Q3 25
17.7%
2.0%
Q2 25
26.8%
-63.6%
Q1 25
7.7%
-32.4%
Q4 24
26.4%
37.5%
Q3 24
13.7%
9.8%
Q2 24
2.1%
-12.0%
Q1 24
9.5%
Capex Intensity
PBYI
PBYI
VIRC
VIRC
Q4 25
0.0%
2.7%
Q3 25
0.0%
1.5%
Q2 25
0.0%
7.2%
Q1 25
0.1%
3.3%
Q4 24
0.0%
3.0%
Q3 24
0.0%
1.7%
Q2 24
0.0%
2.3%
Q1 24
0.0%
1.5%
Cash Conversion
PBYI
PBYI
VIRC
VIRC
Q4 25
Q3 25
1.10×
0.31×
Q2 25
2.41×
-26.00×
Q1 25
1.21×
Q4 24
3.98×
Q3 24
0.54×
0.74×
Q2 24
-2.11×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons